ATR-258 is a GRK2-biased partial agonist of beta2AR. It acts as a competitive antagonist of beta1AR and exhibits weak partial agonist activity on beta3AR at a concentration of 10 µM. ATR-258 enhances glycemic control and reduces lipid accumulation in obese mice with minimal side effects. It is applicable in research on type 2 diabetes (T2DM).
Molekulargewicht:
212.26
CAS Nummer:
[2301983-88-8]
Formel:
C11H17FN2O
Target-Kategorie:
Adrenergic Receptor
T210670
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten